Dynavax Technologies Corp buy klostergang
Summary
This prediction ended on 01.02.18 with a price of €13.20. With a performance of 159.33% the BUY prediction by klostergang was a big success. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Dynavax Technologies Corp | 2.305% | 2.305% | 12.794% | 28.375% |
| iShares Core DAX® | 0.000% | -2.064% | 13.111% | 16.685% |
| iShares Nasdaq 100 | 0.626% | -2.884% | 37.744% | 43.441% |
| iShares Nikkei 225® | 1.568% | -5.892% | 19.592% | 4.617% |
| iShares S&P 500 | 0.334% | -2.281% | 27.745% | 41.046% |
Comments by klostergang for this prediction
In the thread Dynavax Technologies Corp diskutieren
klostergang stimmt der fundamentalen Bewertung mit dem Ergebnis 'unterbewertet' zu
Last Monday, it was annouced that the FDA's Vaccines and Related Biological Products Advisory
Committee will review its marketing application for hepatitis B vaccine candidate HEPLISAV-B on July 28. The PDUFA date for the company's lead biologic candidate remains August 10th.
William Blair is modeling a 70% chance of approval given this view for this BLA (Biologic License Application) and pegs peak sales of HEPLISAV-B at $650 million in the United States. For a company with an approximate market capitalization of $250 million, obviously this would be a huge deal for Dynavax and its stock price.
In addition, Dynavax has a promising oncology compound "SD-101" that is being paired in combination with Merck's (NYSE:MRK) Keytruda that will have more trial visibility throughout 2017. It also has an asthma candidate in parternship with AstraZeneca (NYSE:AZN) that is conducting Phase II trials for the compound.
Stopped prediction by klostergang for Dynavax Technologies Corp
Dynavax Technologies Corp
15.03.20
04.11.21
17.06.21
Dynavax Technologies Corp
02.02.18
02.05.19
02.05.19